PIN Pharma Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
PIN Pharma General Information
Description
Developer of precision immune stimulants designed to link innate and adaptive immune systems. The company's stimulants target breast and colon cancer to overcome cancer-mediated immune suppression, enabling physicians to perform treatment in an enhanced way.
Contact Information
Website
www.pinpharma.comCorporate Office
- 55 Broadway
- Suite 315
- New York, NY 10006
- United States
Corporate Office
- 55 Broadway
- Suite 315
- New York, NY 10006
- United States
PIN Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Apr-2021 | 00.000 | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 01-Jan-2012 | 00.000 | 00.000 | 000.00 | Completed | Startup |
PIN Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 000 |
PIN Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PIN Pharma Patents
PIN Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9663556-B2 | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | Active | 04-Oct-2013 | 0000000000 | 000 |
| US-20150098960-A1 | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | Active | 04-Oct-2013 | 0000000000 | 0 |
| US-20190030117-A1 | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | Inactive | 04-Oct-2013 | 0000000000 | |
| CA-2926221-A1 | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment | Inactive | 04-Oct-2013 | 0000000000 | |
| US-10159707-B2 | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | Inactive | 04-Oct-2013 | A61K38/162 | 000 |
PIN Pharma Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Colin Bier Ph.D | Co-Inventor, Chief Executive Officer, Chief Scientific Officer & President | |
| Joshua Goldberg | Co-Inventor |
PIN Pharma Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Richard Rathmann JD | Self | Board Member | 000 0000 |
| William Gedale JD | NGN Capital | Chairman | 000 0000 |
PIN Pharma FAQs
-
When was PIN Pharma founded?
PIN Pharma was founded in 2011.
-
Who is the founder of PIN Pharma?
Colin Bier Ph.D and Joshua Goldberg are the founders of PIN Pharma.
-
Who is the CEO of PIN Pharma?
Colin Bier Ph.D is the CEO of PIN Pharma.
-
Where is PIN Pharma headquartered?
PIN Pharma is headquartered in New York, NY.
-
What industry is PIN Pharma in?
PIN Pharma’s primary industry is Biotechnology.
-
Is PIN Pharma a private or public company?
PIN Pharma is a Private company.
-
What is PIN Pharma’s current revenue?
The current revenue for PIN Pharma is 000000.
-
How much funding has PIN Pharma raised over time?
PIN Pharma has raised $6.75M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
